High concordance of findings obtained from transgluteal magnetic resonance imaging ‐ and transrectal ultrasonography‐guided biopsy as compared with prostatectomy specimens
暂无分享,去创建一个
G. Sauter | T. Schlomm | S. Steurer | T. Krech | R. Simon | S. Minner | M. Tsourlakis | H. Heinzer | M. Graefen | H. Huland | C. Koop | Meike Adam | Sebastian Dwertmann Rico | A. Lumiani
[1] H. Samaratunga,et al. MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature , 2018, World Journal of Urology.
[2] T. Barrett,et al. Lesion Targeted CT-Guided Transgluteal Prostate Biopsy in Combination With Prebiopsy MRI in Patients Without Rectal Access , 2016, Urology case reports.
[3] A. Haese*,et al. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. , 2016, European urology.
[4] E. Klein,et al. CT-Guided Transgluteal Biopsy for Systematic Random Sampling of the Prostate in Patients Without Rectal Access. , 2015, AJR. American journal of roentgenology.
[5] Nan Zhang,et al. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. , 2015, European urology.
[6] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[7] Pierre Mozer,et al. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography‐guided biopsies for the diagnosis of localised prostate cancer , 2015, BJU international.
[8] P. Asbach,et al. Die Echtzeit-MRT/US-Fusionsbiopsie in Patienten mit und ohne Vorbiopsie mit Verdacht auf ein Prostatakarzinom , 2014, Aktuelle Urologie.
[9] David Y. Lu,et al. Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. , 2014, The Journal of urology.
[10] P. Febbo,et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.
[11] William L. Welbourn,et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. , 2014, The Journal of urology.
[12] F. Schröder,et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. , 2014, European urology.
[13] N. Salem,et al. Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies , 2014, World Journal of Urology.
[14] Baris Turkbey,et al. Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. , 2014, The Journal of urology.
[15] Yejun Qin,et al. Magnetic resonance imaging‑directed biopsy improves the prediction of prostate cancer aggressiveness compared with a 12‑core transrectal ultrasound‑guided prostate biopsy. , 2014, Molecular medicine reports.
[16] Shyam Natarajan,et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. , 2014, European urology.
[17] E. Crawford,et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry , 2014, Current medical research and opinion.
[18] Anirban P. Mitra,et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.
[19] Baris Turkbey,et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. , 2013, European urology.
[20] Anirban P. Mitra,et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy , 2013, Prostate Cancer and Prostatic Disease.
[21] Heinz-Peter Schlemmer,et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. , 2013, The Journal of urology.
[22] Xavier Leroy,et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. , 2013, Radiology.
[23] William L. Welbourn,et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. , 2013, International journal of radiation oncology, biology, physics.
[24] Anirban P. Mitra,et al. Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.
[25] S. Zangos,et al. 1.5-T Magnetic Resonance–Guided Transgluteal Biopsies of the Prostate in Patients With Clinically Suspected Prostate Cancer: Technique and Feasibility , 2013, Investigative radiology.
[26] Naira Muradyan,et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. , 2013, The Journal of urology.
[27] Baris Turkbey,et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. , 2012, The Journal of urology.
[28] Thomas Hambrock,et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. , 2012, European urology.
[29] Hashim Uddin Ahmed,et al. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? , 2012, The Lancet. Oncology.
[30] M. Jordá,et al. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. , 2012, European urology.
[31] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[32] J. Verhaegen,et al. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis? , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[33] M. Cooperberg,et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Schilling,et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy , 2012, World Journal of Urology.
[35] Mana Ishibashi,et al. Detection and Localization of Prostate Cancer With the Targeted Biopsy Strategy Based on ADC Map: A Prospective Large-Scale Cohort Study , 2012, Journal of magnetic resonance imaging : JMRI.
[36] G. Haber,et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detection , 2011, BJU international.
[37] Ralph Strecker,et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. , 2011, Radiology.
[38] Ralph Strecker,et al. Areas Suspicious for Prostate Cancer : MR – guided Biopsy in Patients with at Least One Transrectal US-guided Biopsy with a Negative Finding — Multiparametric MR Imaging for Detection and Biopsy Planning 1 , 2011 .
[39] Tsuyoshi Mitake,et al. Real‐time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data , 2010, International journal of urology : official journal of the Japanese Urological Association.
[40] Thomas Hambrock,et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. , 2010, The Journal of urology.
[41] W. Gerald,et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.
[42] A P Labanaris,et al. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate , 2009, Prostate Cancer and Prostatic Diseases.
[43] Deanna L Langer,et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. , 2008, Radiology.
[44] G. Haas,et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. , 2008, The Canadian journal of urology.
[45] Thomas J. Vogl,et al. MR-compatible assistance system for punction in a high-field system: device and feasibility of transgluteal biopsies of the prostate gland , 2007, European Radiology.
[46] B. Kiefer,et al. Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device , 2006, European Radiology.
[47] L. True. Surgical pathology examination of the prostate gland. Practice survey by American society of clinical pathologists. , 1994, American journal of clinical pathology.
[48] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[49] C. Catalano,et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. , 2015, Urologic oncology.
[50] P. Asbach,et al. [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer]. , 2014, Aktuelle Urologie.
[51] Andrew B Rosenkrantz,et al. Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. , 2014, AJR. American journal of roentgenology.
[52] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[53] Mark Emberton,et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.
[54] Thomas Hambrock,et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. , 2012, European urology.
[55] S. Zangos,et al. MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results , 2004, European Radiology.
[56] K. Ahrar,et al. Various approaches for CT-guided percutaneous biopsy of deep pelvic lesions: anatomic and technical considerations. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.
[57] A. Marx,et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .
[58] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.